- Home
- VINP vs DRUG Comparison
VINP vs DRUG Comparison
Compare VINP & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.6M | 856.4M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VINP | DRUG |
|---|---|---|
| Price | $12.75 | $87.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $114.00 |
| AVG Volume (30 Days) | 38.6K | ★ 86.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $66.95 | N/A |
| Revenue Next Year | $20.64 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $23.18 |
| 52 Week High | $13.61 | $123.75 |
Technical Indicators
Market Signals| Indicator | VINP | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 56.55 |
| Support Level | $11.90 | $78.00 |
| Resistance Level | $12.64 | $84.66 |
| Average True Range (ATR) | 0.41 | 5.56 |
| MACD | 0.00 | 0.96 |
| Stochastic Oscillator | 39.25 | 94.41 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.